 |
|
Blood-clotting protein modified for people with hard-to-treat hemophilia
May 20, 2008Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.
With a shortage of the blood-clotting protein Factor VIII (FVIII), people with Hemophilia A typically receive injections of FVIII derived from plasma or produced synthetically to control potentially life-threatening episodes of bleeding. Unfortunately as many as 1 in 3 people with Hemophilia A produce inhibitor antibodies, which attack the externally-administered FVIII and negate its blood-clotting benefits.
To combat this problem, scientists in the laboratory of Sudhir Paul, Ph.D., at The University of Texas Medical School at Houston, developed a chemically modified version of FVIII which during laboratory tests neutralized these inhibitor antibodies, thus paving the way for the correction of the blood-coagulating process. The modification is called electrophilic FVIII analog (E-FVIII).
"It's a two-step process,'' said Paul, the senior author. "The E-FVIII permanently inactivates the antibodies that inhibit blood clotting in 20 to 30 percent of patients receiving Factor VIII replacement therapy. Once the antibodies are cleared, additional FVIII can be injected." The study involved blood donated by eight people with FVIII-resistant Hemophilia A.
Today, people with FVIII-resistant Hemophilia A have limited treatment options, said co-author Keri Smith, Ph.D., an assistant professor of pathology and laboratory medicine at the UT Medical School at Houston. Those options include bypass therapy or multiple FVIII injections. Both are prohibitively expensive and often ineffective to meet emergency blood-clotting needs.
E-FVIII might provide a more economically feasible method of treating inhibitor antibodies, Smith said.
There is no cure for Hemophilia A, and it primarily affects males. About one of every 7,000 males born in the United States has this condition. A person with hemophilia bleeds longer than a person without hemophilia.
Stephanie Planque, who is lead author and is working towards her Ph.D. degree, helped conceive the chemical inactivation principle behind the study. The modified FVIII analog was produced by pathology faculty Hiroaki Taguchi, Ph.D., and Yasuhiro Nishiyama, Ph.D., using newly developed synthesis methods. Miguel Escobar, M.D., of the department of pediatrics and internal medicine at the UT Medical School at Houston and the Gulf States Hemophilia and Thrombophilia Center, led the clinical aspects of the work, and Kathleen Pratt, Ph.D., at the Puget Sound Blood Center and Division of Hematology, University of Washington, Seattle, contributed a genetically-produced protein that helped the study reach its conclusions.
According to Paul, the next step involves clinical trials. "E-FVIII is a first generation reagent. Future genetic and chemical manipulations may help develop improved E-FVIII analogs," Paul wrote in the paper.
University of Texas Health Science Center at Houston
"It's a two-step process,'' said Paul, the senior author. "The E-FVIII permanently inactivates the antibodies that inhibit blood clotting in 20 to 30 percent of patients receiving Factor VIII replacement therapy. Once the antibodies are cleared, additional FVIII can be injected." The study involved blood donated by eight people with FVIII-resistant Hemophilia A.
Today, people with FVIII-resistant Hemophilia A have limited treatment options, said co-author Keri Smith, Ph.D., an assistant professor of pathology and laboratory medicine at the UT Medical School at Houston. Those options include bypass therapy or multiple FVIII injections. Both are prohibitively expensive and often ineffective to meet emergency blood-clotting needs.
E-FVIII might provide a more economically feasible method of treating inhibitor antibodies, Smith said.
There is no cure for Hemophilia A, and it primarily affects males. About one of every 7,000 males born in the United States has this condition. A person with hemophilia bleeds longer than a person without hemophilia.
Stephanie Planque, who is lead author and is working towards her Ph.D. degree, helped conceive the chemical inactivation principle behind the study. The modified FVIII analog was produced by pathology faculty Hiroaki Taguchi, Ph.D., and Yasuhiro Nishiyama, Ph.D., using newly developed synthesis methods. Miguel Escobar, M.D., of the department of pediatrics and internal medicine at the UT Medical School at Houston and the Gulf States Hemophilia and Thrombophilia Center, led the clinical aspects of the work, and Kathleen Pratt, Ph.D., at the Puget Sound Blood Center and Division of Hematology, University of Washington, Seattle, contributed a genetically-produced protein that helped the study reach its conclusions.
According to Paul, the next step involves clinical trials. "E-FVIII is a first generation reagent. Future genetic and chemical manipulations may help develop improved E-FVIII analogs," Paul wrote in the paper.
University of Texas Health Science Center at Houston
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Green Tea Jellyfish Black Holes Esophageal Cancer Biodiversity Radiation dose Spinal Cord Injury Spectroscopy Back Pain Brain Disease Cerebral Malaria Biofilms Mammograms Glucose Morphine Graphene Neutron Heart Transplant Quantum Computers Antibiotic Resistance Type 2 Diabetes Pulmonary Fibrosis Carbon Footprint Nuclear Power Pycnogenol
See More: Science News Tags
Hemophilia Current Events and Hemophilia News RSSJumping genes discovery 'challenges current assumptions'
Jumping genes do most of their jumping, not during the development of sperm and egg cells, but during the development of the embryo itself.
Gene therapy technique thwarts cancer by cutting off tumor blood supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply.
Gene therapy demonstrates benefit in patients with rheumatoid arthritis
Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.
Redesigned protein accelerates blood clotting
Researchers have made several, subtle changes in the structure of a key protein, dramatically increasing its ability to drive blood clotting, according to a study published in a December edition of the Journal of Thrombosis and Haemostasis.
Mapping a clan of mobile selfish genes
Much of human DNA is the genetic equivalent of e-mail spam: short repeated sequences that have no obvious function other than making more of themselves.
UF researchers develop improved gene therapy agent
Replacing one amino acid on the surface of a virus that shepherds corrective genes into cells could be the breakthrough scientists have needed to make gene therapy a more viable option for treating genetic diseases such as hemophilia, University of Florida researchers say.
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume.
New stem cell technique improves genetic alteration
UC Irvine researchers have discovered a dramatically improved method for genetically manipulating human embryonic stem cells, making it easier for scientists to study and potentially treat thousands of disorders ranging from Huntington's disease to muscular dystrophy and diabetes.
NHLBI Issues First U.S. von Willebrand Disease Clinical Practice Guidelines
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.
First demonstration of muscle restoration in an animal model of Duchenne muscular dystrophy
Using a new type of drug that targets a specific genetic defect, researchers at the University of Pennsylvania School of Medicine, along with colleagues at PTC Therapeutics Inc. and the University of Massachusetts Medical School, have for the first time demonstrated restoration of muscle function in a mouse model of Duchenne's muscular dystrophy (DMD).
More Hemophilia Current Events and Hemophilia News Articles
 |
Textbook of Hemophilia by Wiley-Blackwell The only up-to-date definitive reference source on hemophilia This book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders. Textbook of Hemophilia is ideal for: Why Buy This... |
 |
Textbook of Hemophilia by Christine A. Lee (Editor), Erik E. Berntorp MD PhD (Editor), W. Keith Hoots MD (Editor), Louis M. Aledort MD (Editor) The only up-to-date definitive reference source on hemophilia This book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders. Textbook of Hemophilia is ideal for: Why Buy This... |
 |
Understanding Hemophilia Part of the award winning public television series Healthy Body/Healthy Mind. Bleeding due to a cut or wound can be a little scary at times, especially if your child is a hemophiliac. Hemophiliacs lack specific blood proteins known as clotting factors that our bodies need to control bleeding following an injury. Fortunately, there is far more hope than ever before for these young patients. This episode features individuals with hemophilia who are successfully managing the disease in a manner that allows them to enjoy active and productive lives. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Chinese Herbal Medicine for Hemophilia by Hsin Kuang Herbal Store Asbestosis is a serious lung disease caused when asbestos fibers are inhaled and become lodged in the inner layers of the lungs. Asbestosis is not a type of cancer, and it is different from malignant mesothelioma. Malignant mesothelioma is a type of cancer. When malignant mesothelioma occurs in the lungs, it is called pleural mesothelioma. Some patients do acquire asbestosis and then develop pleural mesothelioma. Asbestosis develops over time as the asbestos fibers cause inflammation in the lungs and the development of fibrosis or scar tissue. The diagnosis of asbestosis occurs when the scar tissue becomes large enough to be identified on an x-ray. As the scar tissue expands throughout the lungs, the lungs become increasingly dysfunctional and breathing becomes labored. Asbestosis can... |
|
Hemophilia Awareness Ribbon Mouse Pad by MyHeritageWear.com | |
|
World Federation of Hemophilia Membership by World Federation of Hemophilia | |
 |
Hemophilia Care in the New Millennium by Springer These are the proceedings of the international symposium to honor Dr. Harold R. Roberts, held in Chapel Hill, North Carolina in April of 1999. The volume covers prions and viral transmissions, unexplained aspects of hemophilia and hemostasis, novel approaches to therapy, and inhibitor development in hemophilia patients. |
 |
Hemophilia (Genes and Disease) by Michelle Raabe (Author) For many people, bumping into a chair or getting a paper cut means momentary pain, followed by quick healing. But for those with hemophilia, a disease that renders its sufferers unable to clot blood effectively and control hemorrhaging after minor injuries, the healing time can be much more arduous. Resulting from mutations in genes that code for blood proteins necessary for clotting, hemophilia is an ancient, hereditary disease that usually affects males and can be classified as severe, moderate, or mild. "Hemophilia", a detailed and easy-to-read guide filled with informative stories of the disease's history, strives to educate readers about the science of hemophilia, while emphasizing how people with this disease can live full and productive lives. The development and technology behind... |
 |
Hemophilia and Your Child: Interactive Education and Support for Parents by Bayer, Inc. Healthcare Division Hemophilia and Your Child is an interactive program designed to provide education and support to parents raising children with hemophilia. This CD-Rom has been developed by a group of hemophilia nurses, physiotherapists, physicians, parents, and Bayer in collaboration with the Canadian Hemophilia Society. This program integrates a variety of learning styles and adapts to the user's pace and interests. The content was developed with the help of the advisory board and a team of medical researches and writers. A feature of this CD is video clips of parents discussing the challenges of living with hemophilia, providing realistic peer education. |
|
An Unexpected Life Living with Hemophilia 58 minute documentary that captures a slice of living history and creates and inspirational message about surviving with hemophilia and related bleeding disorders. |
| © 2009 BrightSurf.com |